10.50 (0.72%)
As of May 27, 2022
Source:
We are a clinical-stage biotechnology company focused on developing and commercializing our proprietary technology to harness the power of the immune system to combat cancer. Our product candidate, vidutolimod, is an advanced generation Toll-like receptor 9 (TLR9) agonist delivered as a non-infectious biologic virus-like particle (VLP) utilizing a CpG-A oligonucleotide as a key component. When injected into a tumor, vidutolimod is designed to trigger the bodys innate immune system, thereby altering the tumor microenvironment and directing activated anti-tumor T cells to attack both the injected tumor and also tumors throughout the body.
| Country | United States |
| Headquarters | cambridge, massachusetts |
| Phone Number | 978-503-2124 |
| Industry | manufacturing |
| CEO | Alan Bash |
| Website | clinicaltrials.gov |